POSTER: Impact of adding Viagenpumatucel-L (HS-110) to Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Patients with Low Levels of Tumor Infiltrating Lymphocytes
Summary View a scientific, collaborative success with our client, Heat Biologics, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 medical oncology
POSTER: Image Analysis-Based Identification and Quantification of Macrophages in PD-L1 (22C3) Stained NSCLC Tissue Sections Without Additional Macrophage-Specific Staining
ABSTRACT PD-L1 positivity in tumor-associated macrophages has been related to a favorable response to anti-PD-1 and PD-L1 targeted therapies. This concept has driven interest in
POSTER: Protein Tyrosine Kinase 7 (PTK7) Biomarker Analysis in Patients treated with PF-06647020, a PTK7 Antibody-Drug Conjugate (ADC), in a Phase I Dose Expansion Study
BACKGROUND F-06647020, an ADC comprising a humanized monoclonal antibody against PTK7, a cleavable valine-citrulline linker, and an auristatin payload, is being investigated in an ongoing
POSTER: Comprehensive Image Analysis Of Immunostained NSCLC Tissues Provides Necessary Context For Immune Oncology Biomarker Profiling
ABSTRACT Manual pathology assessments of Immunohistochemistry (IHC) markers in immuneoncology (IO) is often challenging and results can be highly variable. Measuring biomarker presence in IO
POSTER: Combined Immunohistochemistry And NGS-Based Patient Profiling For Predicting Anti-PD-1/PD-L1 Therapy Response
ABSTRACT There are several different modalities of predictive tests which support response to anti-PD-1/PD-L1 inhibitors therapy, including PD-L1 expression by immunohisto chemistry (PD-L1 IHC), mismatch
POSTER: Artificial Intelligence Assisted Macrophage Identification in Tumor Biopsies
BACKGROUND: Understanding response to immunotherapy requires accurate and complete characterization of tumor-associated immune cells in order to fully contextualize the immuno-oncology biomarker expression. Current standard
